IL32 and Miyoshi myopathy: Besides identifying IL-32 as a potential prognostic biomarker and treatment target in MM, our results provide insight into the metabolic functions of IL-32, which may be further exploited in other cancers and inflammatory diseases where IL-32 is known to play a central role.